Research & Development


  • Image attribution tooltip
    Retrieved from Diego Camargo/PharmaVoice on May 17, 2022
    Podcast

    Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson

    The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.

    By May 18, 2022
  • Image attribution tooltip
    Permission granted by SpringWorks/Jim Cassidy
    Profile

    Jumping into pharma with big plans at a small company

    SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.

    By Alexandra Pecci • May 17, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Q&A

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    By Kelly Bilodeau • May 17, 2022
  • Image attribution tooltip
    Natali_Mis via Getty Images
    Q&A

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    By May 17, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Are digital DCTs the answer for rare diseases?

    How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.

    By Kim Ribbink • May 16, 2022
  • Image attribution tooltip
    iStock via Getty Images

    After 40 years, researchers discover new frontiers in the fight against HIV

    Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.

    By May 16, 2022
  • Image attribution tooltip
    Permission granted by TauRx
    Profile

    With the shine of amyloid fading, tau is a rising star in Alzheimer's

    The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.

    By May 11, 2022
  • Image attribution tooltip
    Stock via Getty Images

    In the hot pharma talent market, execs battle these recruitment misconceptions

    One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.

    By May 11, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

    New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

    By Kelly Bilodeau • May 10, 2022
  • Image attribution tooltip
    Permission granted by Replimune/Philip Astley-Sparke

    Where hope and uncertainty meet: A cutting-edge cancer developer's winding road

    Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.

    By Alexandra Pecci • May 9, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    By May 9, 2022
  • Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    Ultra-sensitive tests bring biomarkers into the drug development forefront

    An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.

    By May 5, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Amgen's Dr. Jane Parnes

    As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.

    By May 4, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Profile

    Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine

    After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.

    By , May 4, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Profile

    From cancer survivor to clinical trial innovator

    How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.

    By Kelly Bilodeau • May 3, 2022
  • Image attribution tooltip
    Stock via Getty Images

    A nuclear threat spurs France's Medesis to advance radiation therapy

    In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.

    By Kelly Bilodeau • May 2, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    By May 2, 2022
  • Image attribution tooltip

    Permission granted by Alan Millar. 

    Q&A

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    By Kim Ribbink • April 28, 2022
  • Image attribution tooltip

    Permission granted by Laura Randa. 

    Profile

    Laura Randa's aim to break down mental healthcare barriers for disabled patients

    Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.

    By Alexandra Pecci • April 27, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan

    As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.

    By April 27, 2022
  • Image attribution tooltip
    D-Keine via Getty Images
    Profile

    Mouse vs. machine: Using AI to solve the animal testing model in pharma

    Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

    By April 26, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    By Kelly Bilodeau • April 26, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    By , April 25, 2022
  • Image attribution tooltip
    Stock via Getty Images

    From the fringes to the forefront — the mRNA era has taken hold of pharma

    A look at what’s next for the industry’s buzziest technology.

    By Kim Ribbink • April 22, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    By Alexandra Pecci • April 21, 2022